Published in JAMA on September 12, 1995
Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. BMJ (2010) 7.15
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene (2007) 4.81
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer (2006) 2.76
Considerations for observational research using large data sets in radiation oncology. Int J Radiat Oncol Biol Phys (2014) 2.06
A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med (1997) 2.01
Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol (2009) 1.89
Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ (1998) 1.77
Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group. Eur Urol (2007) 1.60
Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Can Urol Assoc J (2009) 1.51
The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ (2000) 1.30
Cancer survivorship and aging : moving the science forward. Cancer (2008) 1.23
Treatment strategies for high-risk locally advanced prostate cancer. Nat Rev Urol (2010) 1.19
Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells. Biochem Pharmacol (2008) 1.13
Screening for Prostate Cancer: A Review of the ERSPC and PLCO Trials. Rev Urol (2009) 1.12
Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features. Am J Pathol (2001) 1.11
Prostate-specific antigen-based screening: controversy and guidelines. BMC Med (2015) 1.08
Prostate cancer: 2. Natural history. CMAJ (1998) 1.06
Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer (2009) 1.04
The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. CMAJ (2000) 1.02
Stage at diagnosis and survival in a multiethnic cohort of prostate cancer patients. Am J Public Health (2003) 0.97
Radical prostatectomy as treatment for prostate cancer. CMAJ (2003) 0.96
Management of high-risk localized prostate cancer. Adv Urol (2011) 0.93
Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics. Asian J Androl (2012) 0.92
Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients. Health Serv Res (1999) 0.92
Racial differences in survival among men with prostate cancer and comorbidity at time of diagnosis. Am J Public Health (2004) 0.90
Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: initial results. Eur Radiol (2010) 0.90
The role of radical prostatectomy in high-risk prostate cancer. Prostate Int (2013) 0.89
Selecting candidates for radical prostatectomy. Rev Urol (2000) 0.89
Reduced mortality: the unexpected impact of a telephone-based care management intervention for older adults in managed care. Health Serv Res (2007) 0.89
The role of alpha-blockers in the management of prostate cancer. Expert Opin Pharmacother (2004) 0.88
Presenting treatment options to men with clinically localized prostate cancer: the acceptability of active surveillance/monitoring. J Natl Cancer Inst Monogr (2012) 0.87
Expectant management as an option for men with stage T1c prostate cancer: a preliminary study. World J Urol (1997) 0.87
Vascular targeted photodynamic therapy for localized prostate cancer. Rev Urol (2008) 0.85
Prostate cancer management: (1) an update on localised disease. Postgrad Med J (2003) 0.85
Nomogram using transrectal ultrasound-derived information predicting the detection of high grade prostate cancer on initial biopsy. Prostate Int (2013) 0.83
Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate. World J Urol (1997) 0.82
Managed care market share and primary treatment for cancer. Health Serv Res (2006) 0.81
Detection of prostate cancer with three-dimensional transrectal ultrasound: correlation with biopsy results. Br J Radiol (2011) 0.81
Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. World J Urol (1997) 0.80
The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc (2000) 0.79
Factors influencing the choice of 5-HT3-receptor antagonist antiemetics: focus on elderly cancer patients. Support Care Cancer (2004) 0.79
Prostate cancer screening: waiting for Godot. CMAJ (1998) 0.79
Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Med (2016) 0.79
Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer. Neoplasia (2007) 0.77
Quality of preventive care before and after prostate cancer diagnosis. J Mens Health (2015) 0.76
Selecting treatment for high-risk, localized prostate cancer: the case for radical prostatectomy. Rev Urol (2002) 0.76
Acknowledging unreported problems with active surveillance for prostate cancer: a prospective single-centre observational study. BMJ Open (2016) 0.75
Consideration of comorbidity in risk stratification prior to prostate biopsy. Cancer (2013) 0.75
Survival and conservative treatment for localized prostate cancer. JAMA (1996) 0.75
Screening for prostate cancer. Key studies have only just started. BMJ (1998) 0.75
Molecular profiling of prostatic acinar morphogenesis identifies PDCD4 and KLF6 as tissue architecture-specific prognostic markers in prostate cancer. Am J Pathol (2012) 0.75
Should we and can we cure prostate cancer? West J Med (1996) 0.75
Localized prostate cancer: early intervention or expectant therapy? J R Soc Med (1997) 0.75
The role of postoperative radiotherapy in prostate cancer patients. Contemp Oncol (Pozn) (2013) 0.75
Breast cancer clinical and translational research: analogies and implications for prostate cancer. Rev Urol (2007) 0.75
Survival and conservative treatment for localized prostate cancer. JAMA (1996) 0.75
Patient Preferences for Primary Care Provider Roles in Breast Cancer Survivorship Care. J Clin Oncol (2017) 0.75
Is Prostate Biopsy Recommended in Turkish Men with a Prostate-Specific Antigen Level between 2.5 and 4 ng/mL? Curr Ther Res Clin Exp (2017) 0.75
Priorities in future research in prostate cancer screening. Eur J Epidemiol (2003) 0.75
Health services research in urology. World J Urol (2011) 0.75
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med (1999) 22.81
TRAUMATIC SHOCK. XIII. THE PREVENTION OF IRREVERSIBILITY IN HEMORRHAGIC SHOCK BY VIVIPERFUSION OF THE LIVER. J Clin Invest (1946) 7.56
THE DISTRIBUTION OF RED CELLS AND PLASMA IN LARGE AND MINUTE VESSELS OF THE NORMAL DOG, DETERMINED BY RADIOACTIVE ISOTOPES OF IRON AND IODINE. J Clin Invest (1946) 7.30
TRAUMATIC SHOCK: AN EXPERIMENTAL STUDY INCLUDING EVIDENCE AGAINST THE CAPILLARY LEAKAGE HYPOTHESIS. Ann Surg (1943) 6.41
The Treatment of Acute Renal Failure by Peritoneal Irrigation. Ann Surg (1946) 6.23
Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst (1992) 6.18
TRAUMATIC SHOCK. X. THE TREATMENT OF HEMORRHAGIC SHOCK IRREVERSIBLE TO REPLACEMENT OF BLOOD VOLUME DEFICIENCY. J Clin Invest (1945) 5.75
Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med (1994) 5.37
THE TREATMENT OF GASEOUS DISTENTION OF THE INTESTINE BY THE INHALATION OF NINETY-FIVE PER CENT OXYGEN: DESCRIPTION OF AN APPARATUS FOR THE CLINICAL ADMINISTRATION OF HIGH OXYGEN MIXTURES. Ann Surg (1936) 5.03
THE CIRCULATING RED CELL AND PLASMA VOLUME AND THE DISTRIBUTION OF BLOOD IN LARGE AND MINUTE VESSELS IN EXPERIMENTAL SHOCK IN DOGS, MEASURED BY RADIOACTIVE ISOTOPES OF IRON AND IODINE. J Clin Invest (1947) 4.13
Toward consistency in cost-utility analyses: using national measures to create condition-specific values. Med Care (1998) 4.04
A technique for quantitative measurement of endotoxin in human plasma. Proc Soc Exp Biol Med (1971) 3.66
TRAUMATIC SHOCK. I. THE PRODUCTION OF RADIOACTIVE PLASMA PROTEIN FROM AMINO ACIDS CONTAINING RADIOACTIVE SULFUR. J Clin Invest (1943) 3.34
Pregnancy termination in relation to risk of breast cancer. JAMA (1996) 3.04
The Effect of Chemotherapy on the Ileum Subjected to Vascular Injury. Ann Surg (1945) 2.94
Disk-caused nerve compression in patients with acute low-back pain: diagnosis with MR, CT myelography, and plain CT. Radiology (1993) 2.75
TREATMENT OF EXPERIMENTAL UREMIA BY MEANS OF PERITONEAL IRRIGATION. J Clin Invest (1946) 2.68
FURTHER CLINICAL EXPERIENCES WITH NINETY-FIVE PER CENT OXYGEN FOR THE ABSORPTION OF AIR FROM THE BODY TISSUES. Ann Surg (1938) 2.67
The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol (1996) 2.57
TRAUMATIC SHOCK. V. A STUDY OF THE EFFECT OF OXYGEN ON HEMORRHAGIC SHOCK. J Clin Invest (1943) 2.25
Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst (1995) 2.24
THE EFFECT OF BREATHING 95 PER CENT OXYGEN UPON THE INTRALUMINAL PRESSURE OCCASIONED BY GASEOUS DISTENTION OF THE OBSTRUCTED SMALL INTESTINE. Ann Surg (1938) 2.22
A CLINICAL STUDY OF THE PLASMA VOLUME IN ACUTE INTESTINAL OBSTRUCTION. Ann Surg (1940) 2.22
PLASMA TRANSFUSION IN EXPERIMENTAL INTESTINAL OBSTRUCTION. Ann Surg (1940) 2.19
THE ROLE OF THE NERVOUS SYSTEM IN ACUTE INTESTINAL OBSTRUCTION: AN EXPERIMENTAL INVESTIGATION. Ann Surg (1939) 2.13
General relative risk functions for case-control studies. Am J Epidemiol (1985) 2.07
Endotoxaemia in man. Lancet (1972) 2.06
Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med (2000) 2.05
Chasing the dragon: the smoking of heroin and cocaine. J Subst Abuse Treat (1990) 1.94
The Limulus coagulation test for endotoxin. A comparison with other assay methods. Proc Soc Exp Biol Med (1969) 1.92
TRAUMATIC SHOCK. XIV. THE SUCCESSFUL TREATMENT OF HEMORRHAGIC SHOCK BY VIVI-PERFUSION OF THE LIVER IN DOGS IRREVERSIBLE TO TRANSFUSION. J Clin Invest (1947) 1.89
An evaluation of multiple trauma severity indices created by different index development strategies. Med Care (1983) 1.74
Treatment choice and quality of life in patients with choroidal melanoma. Arch Ophthalmol (1999) 1.68
Tear gas--harassing agent or toxic chemical weapon? JAMA (1989) 1.66
Body size and risk of breast cancer. Am J Epidemiol (1997) 1.63
THE EFFECT OF ACUTE INTESTINAL OBSTRUCTION ON THE BLOOD AND PLASMA VOLUMES. Ann Surg (1939) 1.61
TRAUMATIC SHOCK. XV. CARBOHYDRATE METABOLISM IN HEMORRHAGIC SHOCK IN THE DOG. J Clin Invest (1947) 1.61
Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol (1995) 1.59
Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control (2000) 1.56
Traumatic Shock Incurable by Volume Replacement Therapy : A Summary of Further Studies including Observations on the Hemodynamics, Intermediary Metabolism and Therapeutics of Shock. Ann Surg (1945) 1.54
Cost-effectiveness of strategies for detecting diabetic retinopathy. Med Care (1991) 1.51
Bayes' theorem and conditional nonindependence of data in medical diagnosis. Comput Biomed Res (1978) 1.50
Magnetic resonance angiography in progressive renal failure: a technology assessment. Am J Kidney Dis (1995) 1.46
RECENT EXPERIENCES WITH THROMBOPHLEBITIS OF THE LOWER EXTREMITY AND PULMONARY EMBOLISM: THE VALUE OF VENOGRAPHY AS A DIAGNOSTIC AID. Ann Surg (1942) 1.45
Cerebrospinal fluid creatine kinase BB isoenzyme activity and neurologic prognosis after cardiac arrest. Neurology (1997) 1.41
Breast self-examination in relation to the occurrence of advanced breast cancer. J Natl Cancer Inst (1991) 1.40
Screening for abdominal aortic aneurysm in men ages 60 to 80 years. A cost-effectiveness analysis. Ann Intern Med (1993) 1.30
Sleep-disordered breathing and self-reported general health status in the Wisconsin Sleep Cohort Study. Sleep (1998) 1.30
Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. Mol Pharmacol (2001) 1.27
THE PROPHYLAXIS OF PULMONARY EMBOLISM BY DIVISION OF THE FEMORAL VEIN. Ann Surg (1941) 1.27
Further Experiences with Peritoneal Irrigation for Acute Renal Failure: Including a Description of Modifications in Method. Ann Surg (1948) 1.27
THE EFFECT OF HYALURONIDASE ON THE ABSORPTION OF PARENTERALLY ADMINISTERED RADIOACTIVE PLASMA PROTEINS IN THE DOG. J Clin Invest (1949) 1.27
Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. Neuropsychiatry Neuropsychol Behav Neurol (2001) 1.26
Excess of malignant melanomas in women in the British Isles. Lancet (1981) 1.25
TRAUMATIC SHOCK. XI. INTESTINAL ABSORPTION IN HEMORRHAGIC SHOCK. J Clin Invest (1945) 1.24
Self-reported stress and risk of breast cancer. Cancer (1996) 1.23
A psychophysiological study of nightmares and night terrors. 3. Mental content and recall of stage 4 night terrors. J Nerv Ment Dis (1974) 1.23
Detoxification of endotoxin by perfusion of liver and spleen. Proc Soc Exp Biol Med (1967) 1.23
The value of T2 relaxation times to characterize lumbar intervertebral disks: preliminary results. AJNR Am J Neuroradiol (2006) 1.23
An experimental protocol for fertility preservation in prepubertal boys recently diagnosed with cancer: a report of acceptability and safety. Hum Reprod (2009) 1.22
The lung lesion in four different types of shock in rabbits. Arch Surg (1972) 1.22
Fracture history and risk of breast and endometrial cancer. Am J Epidemiol (2001) 1.22
Sunlamp use and the risk of cutaneous malignant melanoma: a population-based case-control study in Connecticut, USA. Int J Epidemiol (1998) 1.21
Risk factors for carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev (2000) 1.20
Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res (1991) 1.16
Health status and hypertension: a population-based study. J Clin Epidemiol (1996) 1.15
STUDIES WITH RADIOACTIVE IODIZED FAT. I. PREPARATION OF RADIOACTIVE FAT WITH OBSERVATIONS ON THE ABSORPTION OF FAT FOLLOWING SUBCUTANEOUS AND INTRAPERITONEAL INJECTION IN DOGS. J Clin Invest (1949) 1.14
Enrollment in and compliance with a community demonstration program of caries prevention for grades kindergarten through 12. J Public Health Dent (1982) 1.12
A global sensitivity test for evaluating statistical hypotheses with nonidentifiable models. Biometrics (2009) 1.11
Recent oral contraceptive use and risk of breast cancer (United States) Cancer Causes Control (1996) 1.10
The nature of resistance to shock. Arch Surg (1969) 1.10
Role of intraintestinal endotoxin in death from peritonitis. Surg Gynecol Obstet (1972) 1.08
Tumor vascularity is not a prognostic factor for malignant melanoma of the skin. Am J Pathol (1995) 1.08
Cutting edge: species specificity of the CC chemokine 6Ckine signaling through the CXC chemokine receptor CXCR3: human 6Ckine is not a ligand for the human or mouse CXCR3 receptors. J Immunol (1999) 1.08
Role of endotoxemia of intestinal origin in early death from large burns. Surg Gynecol Obstet (1974) 1.08
STUDIES WITH RADIOACTIVE IODIZED FAT. II. THE TISSUE DISTRIBUTION OF EMULSIFIED FAT FOLLOWING INTRAVENOUS ADMINISTRATION. J Clin Invest (1949) 1.08
New developments in therapy of refractory traumatic shock. Arch Surg (1968) 1.06
The quality of life of adult survivors of childhood hematopoietic cell transplant. Bone Marrow Transplant (2009) 1.05
A decision theoretic methodology for severity index development. Med Decis Making (1986) 1.04
Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol (2000) 1.03
Side effects after ketamine anesthesia: transient blindness. Anesth Analg (1974) 1.03
Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol (2005) 1.02
Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J Gen Intern Med (1997) 1.00
Sensory disturbances following ketamine anesthesia: recurrent hallucinations. Anesth Analg (1973) 0.99
TRAUMATIC SHOCK. XII. HEMODYNAMIC EFFECTS OF ALTERATIONS OF BLOOD VISCOSITY IN NORMAL DOGS AND IN DOGS IN SHOCK. J Clin Invest (1946) 0.99
A multicenter outcomes analysis of patients with neonatal reflux presenting with prenatal hydronephrosis. J Urol (1999) 0.97
Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev (1996) 0.97
Production of fatal endotoxic shock by vasoactive substances. Gastroenterology (1973) 0.97
Cigarette smoking in relation to risk of large bowel cancer in women. Cancer Res (1995) 0.96
The intestinal circulation in shock. Gastroenterology (1967) 0.96
Malignant melanoma risk factors by anatomic site: a case-control study and polychotomous logistic regression analysis. Int J Cancer (1996) 0.95
Validation of a melanoma prognostic model. Arch Dermatol (1998) 0.95
Antilymphoma activity of human gamma delta T-cells in mice with severe combined immune deficiency. Cancer Res (1992) 0.94
An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. J Am Acad Dermatol (1992) 0.93
A time-tradeoff method for cost-effectiveness models applied to radiology. Med Decis Making (2000) 0.93
Prolonged anorexia and elevated plasma cytokine levels following myeloablative allogeneic hematopoietic cell transplant. Bone Marrow Transplant (2007) 0.93